In The News
LQR House Inc. Announces Change of Ticker Symbol From "LQR" to "YHC" Effective December 16, 2024
MIAMI BEACH, FL / ACCESSWIRE / December 13, 2024 / LQR House Inc. (the "Company" or "LQR House") (NASDAQ:LQR), a niche e-commerce platform specializing in the spirits and beverage industry, today announced that its shares of common stock will begin trading under the new ticker symbol "YHC" on the Nasdaq Capital Market prior to the market open on December 16, 2024.
Activist investor David Lazar to invest $3M in LQR House
LQR House (NASDAQ:LQR) said on Wednesday that it has entered into a securities purchase agreement with activist investor David Lazar. Under the agreement, Lazar has committed to providing $3M in funding to LQR House.
David E. Lazar Announces Ownership Interest in Minim, Inc.
NEW YORK, Jan. 30, 2024 /PRNewswire/ -- David E. Lazar, an experienced private investor, today filed a Schedule 13D announcing his acquisition of 2,000,000 shares of Series A Convertible Preferred Stock ("Series A Preferred Stock") of Minim, Inc. ("Minim" or the "Company"). Each share of Series A Preferred Stock is convertible into 1.4 shares of the Company's common stock ("Common Stock").
Titan Pharmaceuticals Shares Double on Reverse Merger Deal
Titan Pharmaceuticals shares rallied after the company entered into an agreement to combine with KE Sdn. Bhd. in a reverse merger .Shares in premarket trading on Tuesday more than doubled to $10.38.
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”).
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“TTNP” or the “Company”) with 9.9% of the Company’s outstanding shares, today issued the following statement:
Lionel Messi’s fashion royalties and shipping’s road to Nasdaq
Heidmar is latest shipping company to opt for non-SPAC reverse merger. Some shipping listings are acquired from public companies that have nothing to do with shipping — which makes for some colourful Nasdaq origin stories.
OpGen Announces Acquisition of Preferred Stock by David Lazar
ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”) of the Company at a price of $1.00 per share for aggregate gross proceeds of $3.0 million.
No Product, No Sales, No Prospects? Consider a Reverse Merger
Source: bloomberg.com/news, When all else has failed and a publicly traded company has no product and no prospects, it still has one thing that is worth a pot of gold — its listing.
Minim Rises After Investor David Lazar Buys 2M Preferred Shares
Shares of Minim rose after investor David E. Lazar agreed to buy 2 million preferred shares of the provider of WiFi security software.
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”).
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.
